Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.
Saved in:
| Title: | Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial. |
|---|---|
| Authors: | Morand EF; Centre for Inflammatory Diseases, Monash University, Melbourne, VIC, Australia. Electronic address: eric.morand@monash.edu., Werth VP; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J Crecenz VAMC, Philadelphia, PA, USA., Wenzel J; Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany., Furie R; Division of Rheumatology, Northwell, Great Neck, NY, USA., Dall'Era M; Division of Rheumatology, University of California San Francisco School of Medicine, San Francisco, CA, USA., Sanchez-Guerrero J; Division of Rheumatology, Mount Sinai Hospital/Toronto Western Hospital, University of Toronto, Toronto, ON, Canada., Roy S; Ares Trading SA, an affiliate of Merck KGaA, Eysins, Switzerland., Goodson SG; EMD Serono Research amp; Development Institute, Inc, an affiliate of Merck KGaA, Billerica, MA, USA., Moreau F; EMD Serono Research amp; Development Institute, Inc, an affiliate of Merck KGaA, Billerica, MA, USA., Gühring H; Merck Healthcare KGaA, Darmstadt, Germany., Sgouroudi E; Merck Healthcare KGaA, Darmstadt, Germany., Klopp-Schulze L; Merck Healthcare KGaA, Darmstadt, Germany., Pearson DR; Department of Dermatology, University of Minnesota, Minneapolis, MN, USA. |
| Source: | The Lancet. Rheumatology [Lancet Rheumatol] 2026 Jul; Vol. 8 (7), pp. e513-e527. Date of Electronic Publication: 2026 May 07. |
| Publication Type: | Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase II |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2665-9913 (Electronic) Linking ISSN: 26659913 NLM ISO Abbreviation: Lancet Rheumatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
